Javascript must be enabled to continue!
Treatment of Aggressive Pituitary Adenomas and Carcinomas – An Overview
View through CrossRef
Most pituitary tumours are non-invasive, benign adenomas that remain confined to the sella turcica. Some of them recur, have a rapid growth rate, and invade surrounding tissues. These adenomas, considered aggressive pituitary tumours, are difficult to manage and present problems due to incomplete resection. A pituitary carcinoma is diagnosed when craniospinal and/or systemic metastases are documented. Treatment options for pituitary adenomas are surgery, radiation and drugs. Recent publications report the efficacy of temozolomide in the treatment of aggressive pituitary adenomas and carcinomas. Indications for, results with, and side effects of temozolomide therapy in aggressive pituitary tumours and pituitary carcinomas are reviewed here. Alternative treatment options for resistant or recurrent pituitary tumours are also discussed.
Touch Medical Media, Ltd.
Title: Treatment of Aggressive Pituitary Adenomas and Carcinomas – An Overview
Description:
Most pituitary tumours are non-invasive, benign adenomas that remain confined to the sella turcica.
Some of them recur, have a rapid growth rate, and invade surrounding tissues.
These adenomas, considered aggressive pituitary tumours, are difficult to manage and present problems due to incomplete resection.
A pituitary carcinoma is diagnosed when craniospinal and/or systemic metastases are documented.
Treatment options for pituitary adenomas are surgery, radiation and drugs.
Recent publications report the efficacy of temozolomide in the treatment of aggressive pituitary adenomas and carcinomas.
Indications for, results with, and side effects of temozolomide therapy in aggressive pituitary tumours and pituitary carcinomas are reviewed here.
Alternative treatment options for resistant or recurrent pituitary tumours are also discussed.
Related Results
Neuroimaging Assessment of Aggressive Pituitary Adenomas
Neuroimaging Assessment of Aggressive Pituitary Adenomas
Aggressive pituitary adenomas (APA) are adenomas that show rapid growth, invasiveness, frequent or multiple relapses, or are resistant to conventional therapies. Clinical-imaging a...
Metallothionein Isoform 3 Gene Is Differentially Expressed in Corticotropin-Producing Pituitary Adenomas
Metallothionein Isoform 3 Gene Is Differentially Expressed in Corticotropin-Producing Pituitary Adenomas
In order to search for candidate genes related to pituitary adenoma aggressiveness, the present investigation was intended to compare the mRNA expression profile from a pool of fou...
Treatment of Aggressive Pituitary Adenomas and CarcinomasAn Overview
Treatment of Aggressive Pituitary Adenomas and CarcinomasAn Overview
Most pituitary tumors are non-invasive, benign adenomas that remain confined to the sella turcica. Some of them recur, have a rapid growth rate, and invade surrounding tissues. The...
Plurihormonal pituitary macroadenoma: a case report
Plurihormonal pituitary macroadenoma: a case report
Abstract
Background
Plurihormonal pituitary adenomas are a unique type of pituitary adenomas that secrete two or more pituitary hormones normally as...
A mutation and expression analysis of the oncogene BRAF in pituitary adenomas
A mutation and expression analysis of the oncogene BRAF in pituitary adenomas
SummaryObjective BRAF is an oncogene that is commonly mutated in both melanomas and papillary thyroid carcinomas, usually at position V600E that leads to constitutive activity in...
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract
Introduction: Current study found that about one-third of the incidence of colorectal cancer have genetic related. Hereditary nonpolyposis colorectal cancer...
Growth Hormone (GH) Deficiency (GHD) of Childhood Onset: Reassessment of GH Status and Evaluation of the Predictive Criteria for Permanent GHD in Young Adults
Growth Hormone (GH) Deficiency (GHD) of Childhood Onset: Reassessment of GH Status and Evaluation of the Predictive Criteria for Permanent GHD in Young Adults
GH secretion was reevaluated after completion of GH treatment at a mean age of 19.2 ± 3.2 yr in 35 young adults with childhood-onset GH deficiency (GHD). The patients were subdivid...
COVID-19 induced hypercoagulability and its impact leading to pituitary apoplexy
COVID-19 induced hypercoagulability and its impact leading to pituitary apoplexy
I am writing this letter to address an increasingly high-risk but under-explored complication of pituitary apoplexy in patients who have contracted COVID-19. In light of recent res...

